{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:43:05Z","timestamp":1792618985055,"version":"4.5.0"},"reference-count":274,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>The NCCN Guidelines for Bladder Cancer provide strategies for the diagnosis, treatment, and follow-up of patients with bladder cancer, which is the sixth most common cancer in the United States. Bladder cancer can be divided into 3 categories along a clinical spectrum: (1) non\u2013muscle-invasive bladder cancer; (2) muscle-invasive bladder cancer; and (3) metastatic bladder cancer, with most patients falling into the category of non\u2013muscle-invasive disease. Thus, the selected content featured in this issue specifically covers the clinical presentation and workup of and subsequent management recommendations for non\u2013muscle-invasive bladder cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0022","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:34Z","timestamp":1778754754000},"page":"186-203","source":"Crossref","is-referenced-by-count":16,"title":["Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"Thomas W.","family":"Flaig","sequence":"first","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abern","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"An","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Bangs","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Begovic","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brown","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chan","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chang","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold I.","family":"Chin","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshid A.","family":"Guru","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry W.","family":"Herr","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristos","family":"Kaimakliotis","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilajit","family":"Kundu","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh M.","family":"Lele","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Luckenbaugh","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Patterson","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peyton","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Preston","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Richards","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Seyedin","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Stewart","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly J.","family":"Cassara","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailee","family":"Sliker","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS,  Cancer statistics, 2026. CA Cancer J Clin 2026;76:e70043."},{"key":"B2","article-title":"Cancer stat facts: bladder cancer","unstructured":"National Cancer Institute. Cancer stat facts: bladder cancer. Accessed October 31, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"B3","series-title":"Am Fam Physician","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge KC","year":"2017","unstructured":"DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician 2017;96:507\u2013514."},{"key":"B4","series-title":"Medicine (Baltimore)","first-page":"e8588","article-title":"Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies","volume":"96","author":"Xu Y","year":"2017","unstructured":"Xu Y, Huo R, Chen X, Yu X. Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 2017;96:e8588."},{"key":"B5","series-title":"Eur Urol","first-page":"96","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni S","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I,  Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71:96\u2013108."},{"key":"B6","series-title":"Urol Oncol","first-page":"199","article-title":"Bladder cancer risk from occupational and environmental exposures","volume":"30","author":"Kiriluk KJ","year":"2012","unstructured":"Kiriluk KJ, Prasad SM, Patel AR,  Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012;30:199\u2013211."},{"key":"B7","series-title":"J Clin Oncol","first-page":"406","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo MI","year":"2020","unstructured":"Carlo MI, Ravichandran V, Srinavasan P,  Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol 2020;38:406\u2013414."},{"key":"B8","series-title":"Urol Oncol","first-page":"25.e21","article-title":"Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study","volume":"32","author":"Welty CJ","year":"2014","unstructured":"Welty CJ, Wright JL, Hotaling JM,  Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. Urol Oncol 2014;32:25.e21\u201325."},{"key":"B9","series-title":"J Med Genet","first-page":"464","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post RS","year":"2010","unstructured":"van der Post RS, Kiemeney LA, Ligtenberg MJ,  Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010;47:464\u2013470."},{"key":"B10","series-title":"JAMA","first-page":"1880","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing EM","year":"2018","unstructured":"Messing EM, Tangen CM, Lerner SP,  Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 2018;319:1880\u20131888."},{"key":"B11","series-title":"Eur Urol","first-page":"226","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter J","year":"2018","unstructured":"Bosschieter J, Nieuwenhuijzen JA, van Ginkel T,  Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol 2018;73:226\u2013232."},{"key":"B12","series-title":"Eur Urol","first-page":"231","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?","volume":"69","author":"Sylvester RJ","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S,  Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016;69:231\u2013244."},{"key":"B13","series-title":"Int J Urol","first-page":"631","article-title":"Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: are they necessary?","volume":"10","author":"Fujimoto N","year":"2003","unstructured":"Fujimoto N, Harada S, Terado M,  Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: are they necessary? Int J Urol 2003;10:631\u2013635."},{"key":"B14","series-title":"BJU Int","first-page":"E41","article-title":"The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS)","volume":"110","author":"Gudjonsson S","year":"2012","unstructured":"Gudjonsson S, Blackberg M, Chebil G,  The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS). BJU Int 2012;110:E41\u201345."},{"key":"B15","series-title":"BJU Int","first-page":"1499","article-title":"Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?","volume":"106","author":"Herr HW","year":"2010","unstructured":"Herr HW, Al-Ahmadie H, Dalbagni G, Reuter VE. Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity? BJU Int 2010;106:1499\u20131501."},{"key":"B16","series-title":"BMC Urol","first-page":"12","article-title":"Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study","volume":"10","author":"Matsushima M","year":"2010","unstructured":"Matsushima M, Kikuchi E, Hasegawa M,  Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study. BMC Urol 2010;10:12."},{"key":"B17","series-title":"AJCC Cancer Staging Manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene F,  eds. AJCC Cancer Staging Manual, 8th ed. New York: Springer International Publishing; 2017."},{"key":"B18","series-title":"Rev Urol","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin E","year":"2008","unstructured":"Pasin E, Josephson DY, Mitra AP,  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008;10:31\u201343."},{"key":"B19","series-title":"Hum Pathol","first-page":"95","article-title":"Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion","volume":"44","author":"Brimo F","year":"2013","unstructured":"Brimo F, Wu C, Zeizafoun N,  Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol 2013;44:95\u2013102."},{"key":"B20","series-title":"Ann Diagn Pathol","first-page":"49","article-title":"Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence","volume":"18","author":"Hu Z","year":"2014","unstructured":"Hu Z, Mudaliar K, Quek ML,  Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Ann Diagn Pathol 2014;18:49\u201352."},{"key":"B21","series-title":"Eur Urol","first-page":"378","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn BW","year":"2012","unstructured":"van Rhijn BW, van der Kwast TH, Alkhateeb SS,  A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378\u2013384."},{"key":"B22","series-title":"Eur Urol","first-page":"466","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester RJ","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W,  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466\u2013465; discussion 475\u2013467."},{"key":"B23","series-title":"AJCC Cancer Staging Manual","author":"Edge SB","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC,  AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010."},{"key":"B24","series-title":"J Urol","first-page":"135","article-title":"Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy","volume":"171","author":"Schmidbauer J","year":"2004","unstructured":"Schmidbauer J, Witjes F, Schmeller N,  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135\u2013138."},{"key":"B25","series-title":"J Urol","first-page":"862","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study","volume":"174","author":"Jocham D","year":"2005","unstructured":"Jocham D, Witjes F, Wagner S,  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862\u2013866."},{"key":"B26","series-title":"J Urol","first-page":"62","article-title":"A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer","volume":"178","author":"Grossman HB","year":"2007","unstructured":"Grossman HB, Gomella L, Fradet Y,  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62\u201367."},{"key":"B27","series-title":"J Urol","first-page":"68","article-title":"A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study","volume":"178","author":"Fradet Y","year":"2007","unstructured":"Fradet Y, Grossman HB, Gomella L,  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68\u201373."},{"key":"B28","series-title":"J Urol","first-page":"1907","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl A","year":"2010","unstructured":"Stenzl A, Burger M, Fradet Y,  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907\u20131913."},{"key":"B29","series-title":"BJU Int","first-page":"E297","article-title":"Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study","volume":"108","author":"Hermann GG","year":"2011","unstructured":"Hermann GG, Mogensen K, Carlsson S,  Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study. BJU Int 2011;108:E297\u2013303."},{"key":"B30","series-title":"PLoS One","first-page":"e74142","article-title":"Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials","volume":"8","author":"Yuan H","year":"2013","unstructured":"Yuan H, Qiu J, Liu L,  Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One 2013;8:e74142."},{"key":"B31","series-title":"Eur Urol","first-page":"846","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger M","year":"2013","unstructured":"Burger M, Grossman HB, Droller M,  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846\u2013854."},{"key":"B32","series-title":"Eur Urol","first-page":"624","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink M","year":"2013","unstructured":"Rink M, Babjuk M, Catto JW,  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 2013;64:624\u2013638."},{"key":"B33","series-title":"Bladder Cancer","first-page":"273","article-title":"The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis","volume":"2","author":"Kamat AM","year":"2016","unstructured":"Kamat AM, Cookson M, Witjes JA,  The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer 2016;2:273\u2013278."},{"key":"B34","series-title":"Urology","first-page":"658","article-title":"Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer","volume":"76","author":"Cauberg EC","year":"2010","unstructured":"Cauberg EC, Kloen S, Visser M,  Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology 2010;76:658\u2013663."},{"key":"B35","series-title":"Urol Oncol","first-page":"475","article-title":"Applying narrow-band imaging in complement with white-light imaging cystoscopy in the detection of urothelial carcinoma of the bladder","volume":"31","author":"Chen G","year":"2013","unstructured":"Chen G, Wang B, Li H,  Applying narrow-band imaging in complement with white-light imaging cystoscopy in the detection of urothelial carcinoma of the bladder. Urol Oncol 2013;31:475\u2013479."},{"key":"B36","series-title":"Ther Adv Urol","first-page":"211","article-title":"Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach","volume":"4","author":"Geavlete B","year":"2012","unstructured":"Geavlete B, Jecu M, Multescu R, Geavlete P. Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Ther Adv Urol 2012;4:211\u2013217."},{"key":"B37","series-title":"Int Urol Nephrol","first-page":"451","article-title":"Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a \u201csecond look\u201d matters?","volume":"44","author":"Shen YJ","year":"2012","unstructured":"Shen YJ, Zhu YP, Ye DW,  Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a \u201csecond look\u201d matters? Int Urol Nephrol 2012;44:451\u2013457."},{"key":"B38","series-title":"J Endourol","first-page":"1807","article-title":"Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer","volume":"24","author":"Tatsugami K","year":"2010","unstructured":"Tatsugami K, Kuroiwa K, Kamoto T,  Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol 2010;24:1807\u20131811."},{"key":"B39","series-title":"Eur Urol","first-page":"908","article-title":"A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence","volume":"61","author":"Naselli A","year":"2012","unstructured":"Naselli A, Introini C, Timossi L,  A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol 2012;61:908\u2013913."},{"key":"B40","series-title":"Eur Urol","first-page":"506","article-title":"The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results","volume":"70","author":"Naito S","year":"2016","unstructured":"Naito S, Algaba F, Babjuk M,  The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 2016;70:506\u2013515."},{"key":"B41","series-title":"PLoS One","first-page":"e0170819","article-title":"A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer","volume":"12","author":"Xiong Y","year":"2017","unstructured":"Xiong Y, Li J, Ma S,  A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One 2017;12:e0170819."},{"key":"B42","series-title":"Oncotarget","first-page":"23880","article-title":"Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Kang W","year":"2017","unstructured":"Kang W, Cui Z, Chen Q,  Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget 2017;8:23880\u201323890."},{"key":"B43","series-title":"BJU Int","first-page":"1111","article-title":"A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences","volume":"102","author":"Herr HW","year":"2008","unstructured":"Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102:1111\u20131114."},{"key":"B44","series-title":"Pathologica","first-page":"32","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"115","author":"Raspollini MR","year":"2022","unstructured":"Raspollini MR, Comperat EM, Lopez-Beltran A,  News in the classification of WHO 2022 bladder tumors. Pathologica 2022;115:32\u201340."},{"key":"B45","series-title":"Eur Urol","first-page":"458","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2013part a: renal, penile, and testicular tumours","volume":"82","author":"Moch H","year":"2022","unstructured":"Moch H, Amin MB, Berney DM,  The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2013part a: renal, penile, and testicular tumours. Eur Urol 2022;82:458\u2013468."},{"key":"B46","series-title":"Eur Urol","first-page":"469","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2013part b: prostate and urinary tract tumors","volume":"82","author":"Netto GJ","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM,  The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2013part b: prostate and urinary tract tumors. Eur Urol 2022;82:469\u2013482."},{"key":"B47","series-title":"Urol Oncol","first-page":"15","article-title":"The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis","volume":"39","author":"Kardoust Parizi M","year":"2021","unstructured":"Kardoust Parizi M, Margulis V, Compe Rat E, Shariat SF. The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis. Urol Oncol 2021;39:15\u201333."},{"key":"B48","series-title":"J Urol","first-page":"1129","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori K","year":"2020","unstructured":"Mori K, Abufaraj M, Mostafaei H,  A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2020;204:1129\u20131140."},{"key":"B49","series-title":"Eur Urol Oncol","first-page":"625","article-title":"What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review","volume":"2","author":"Veskimae E","year":"2019","unstructured":"Veskimae E, Espinos EL, Bruins HM,  What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol 2019;2:625\u2013642."},{"key":"B50","series-title":"Semin Oncol","first-page":"619","article-title":"Urachal adenocarcinoma: a clinician's guide for treatment","volume":"39","author":"Siefker-Radtke A.","year":"2012","unstructured":"Siefker-Radtke A. Urachal adenocarcinoma: a clinician's guide for treatment. Semin Oncol 2012;39:619\u2013624."},{"key":"B51","series-title":"Cochrane Database Syst Rev","first-page":"CD009294","article-title":"Intravesical gemcitabine for non- muscle invasive bladder cancer","volume":"1","author":"Jones G","year":"2012","unstructured":"Jones G, Cleves A, Wilt TJ,  Intravesical gemcitabine for non- muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294."},{"key":"B52","series-title":"J Urol","first-page":"86","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester RJ","year":"2005","unstructured":"Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86\u201391; discussion 91\u201392."},{"key":"B53","series-title":"Cochrane Database Syst Rev","first-page":"CD009294","article-title":"Intravesical gemcitabine for non- muscle invasive bladder cancer","volume":"6","author":"Han MA","year":"2021","unstructured":"Han MA, Maisch P, Jung JH,  Intravesical gemcitabine for non- muscle invasive bladder cancer. Cochrane Database Syst Rev 2021;6:CD009294."},{"key":"B54","series-title":"BMC Urol","first-page":"97","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta- analysis of randomized controlled trial","volume":"20","author":"Li R","year":"2020","unstructured":"Li R, Li Y, Song J,  Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta- analysis of randomized controlled trial. BMC Urol 2020;20:97."},{"key":"B55","series-title":"Eur Urol","first-page":"516","article-title":"Bladder-sparing therapy for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection","volume":"86","author":"Li R","year":"2024","unstructured":"Li R, Hensley PJ, Gupta S,  Bladder-sparing therapy for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection. Eur Urol 2024;86:516\u2013527."},{"key":"B56","series-title":"Urol Oncol","first-page":"9.e1","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Gu\u00e9rin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg RL","year":"2022","unstructured":"Steinberg RL, Packiam VT, Thomas LJ,  Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Gu\u00e9rin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol 2022;40:9.e1\u20137."},{"key":"B57","series-title":"J Urol","first-page":"902","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg RL","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N,  Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902\u2013909."},{"key":"B58","series-title":"J Urol","first-page":"589","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree IM","year":"2022","unstructured":"McElree IM, Steinberg RL, Martin AC,  Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer. J Urol 2022;208:589\u2013599."},{"key":"B59","series-title":"JAMA Netw Open","first-page":"e230849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree IM","year":"2023","unstructured":"McElree IM, Steinberg RL, Mott SL,  Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer. JAMA Netw Open 2023;6:e230849."},{"key":"B60","series-title":"J Urol","first-page":"180","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales A","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180\u2013183."},{"key":"B61","series-title":"J Urol","first-page":"90","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle A","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90\u201395."},{"key":"B62","series-title":"Urology","first-page":"1216","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han RF","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216\u20131223."},{"key":"B63","series-title":"BJU Int","first-page":"209","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley MD","year":"2001","unstructured":"Shelley MD, Kynaston H, Court J,  A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209\u2013216."},{"key":"B64","series-title":"BJU Int","first-page":"485","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley MD","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J,  Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485\u2013490."},{"key":"B65","series-title":"Eur Urol","first-page":"247","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom PU","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE,  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247\u2013256."},{"key":"B66","series-title":"J Oncol Pract","first-page":"92","article-title":"Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer BA","year":"2013","unstructured":"Spencer BA, McBride RB, Hershman DL,  Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:92\u201398."},{"key":"B67","series-title":"Eur Urol","first-page":"260","article-title":"Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"Jarvinen R","year":"2009","unstructured":"Jarvinen R, Kaasinen E, Sankila A,  Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260\u2013265."},{"key":"B68","series-title":"Cochrane Database Syst Rev","first-page":"CD011935","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt S","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B,  Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2020;1:CD011935."},{"key":"B69","series-title":"J Urol","first-page":"857","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero P","year":"2013","unstructured":"Gontero P, Oderda M, Mehnert A,  The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 2013;190:857\u2013862."},{"key":"B70","series-title":"Eur Urol","first-page":"766","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester RJ","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ,  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766\u2013773."},{"key":"B71","series-title":"Eur Urol","first-page":"25","article-title":"Bacillus Calmette-","volume":"57","author":"Duchek M","year":"2010","unstructured":"Duchek M, Johansson R, Jahnson S,  Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25\u201331."},{"key":"B72","series-title":"J Urol","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm DL","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD,  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124\u20131129."},{"key":"B73","series-title":"Eur Urol","first-page":"579","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence","volume":"64","author":"Ehdaie B","year":"2013","unstructured":"Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579\u2013585."},{"key":"B74","series-title":"Eur Urol","first-page":"462","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette- Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens J","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R,  Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette- Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462\u2013472."},{"key":"B75","series-title":"Urology","first-page":"682","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle A","year":"2004","unstructured":"Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682\u2013686; discussion 686\u2013687."},{"key":"B76","series-title":"J Urol","first-page":"1964","article-title":"Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester RJ","year":"2002","unstructured":"Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964\u20131970."},{"key":"B77","article-title":"Prescribing information for BCG live, for intravesical use","year":"2009","unstructured":"Prescribing information for BCG live, for intravesical use. 2009. Accessed February 8, 2024. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM163039.pdf"},{"key":"B78","series-title":"Eur Urol","first-page":"429","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden AP","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W,  Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429\u2013434."},{"key":"B79","series-title":"J Urol","first-page":"935","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel M","year":"2006","unstructured":"Colombel M, Saint F, Chopin D,  The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935\u2013939."},{"key":"B80","series-title":"BJU Int","first-page":"633","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano R","year":"2009","unstructured":"Damiano R, De Sio M, Quarto G,  Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity? BJU Int 2009;104:633\u2013639."},{"key":"B81","series-title":"Eur Urol","first-page":"69","article-title":"Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi M","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R,  Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69\u201376."},{"key":"B82","series-title":"J Urol","first-page":"63","article-title":"Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations","volume":"163","author":"Lebret T","year":"2000","unstructured":"Lebret T, Bohin D, Kassardjian Z,  Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 2000;163:63\u201367."},{"key":"B83","series-title":"J Urol","first-page":"1242","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro JA","year":"2005","unstructured":"Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E,  Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242\u20131247."},{"key":"B84","series-title":"Jpn J Clin Oncol","first-page":"395","article-title":"Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG","volume":"35","author":"Mugiya S","year":"2005","unstructured":"Mugiya S, Ozono S, Nagata M,  Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005;35:395\u2013399."},{"key":"B85","series-title":"Eur Urol","first-page":"690","article-title":"Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial \u201cNIMBUS","volume":"78","author":"Grimm MO","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M,  Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial \u201cNIMBUS. Eur Urol 2020;78:690\u2013698."},{"key":"B86","series-title":"Eur Urol Focus","first-page":"481","article-title":"Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari J","year":"2018","unstructured":"Bandari J, Maganty A, MacLeod LC, Davies BJ. Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Gu\u00e9rin. Eur Urol Focus 2018;4:481\u2013484."},{"key":"B87","article-title":"BCG shortage notice","unstructured":"American Urological Association. BCG shortage notice. Accessed February 8, 2024. Available at: https:\/\/www.auanet.org\/bcg-shortage-notice"},{"key":"B88","series-title":"Bladder Cancer","first-page":"293","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar N","year":"2017","unstructured":"Milbar N, Kates M, Chappidi MR,  Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 2017;3:293\u2013303."},{"key":"B89","series-title":"Cancer","first-page":"1893","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non- muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo G","year":"2010","unstructured":"Di Lorenzo G, Perdona S, Damiano R,  Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non- muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010;116:1893\u20131900."},{"key":"B90","series-title":"Eur Urol","first-page":"1123","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich MG","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H,  Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52:1123\u20131129."},{"key":"B91","series-title":"J Urol","first-page":"1189","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou R","year":"2017","unstructured":"Chou R, Selph S, Buckley DI,  Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197:1189\u20131199."},{"key":"B92","series-title":"J Urol","first-page":"476","article-title":"Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial","volume":"166","author":"van der Meijden AP","year":"2001","unstructured":"van der Meijden AP, Brausi M, Zambon V,  Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001;166:476\u2013481."},{"key":"B93","series-title":"J Urol","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg G","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S,  Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761\u2013767."},{"key":"B94","series-title":"World J Urol","first-page":"331","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow LJ","year":"2009","unstructured":"Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 2009;27:331\u2013335."},{"key":"B95","series-title":"Urol Oncol","first-page":"510","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer BN","year":"2010","unstructured":"Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010;28:510\u2013514."},{"key":"B96","series-title":"Eur Urol","first-page":"597","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen Z","year":"2018","unstructured":"Klaassen Z, Kamat AM, Kassouf W,  Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol 2018;74:597\u2013608."},{"key":"B97","series-title":"Int J Urol","first-page":"53","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister C","year":"2015","unstructured":"Pfister C, Kerkeni W, Rigaud J,  Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol 2015;22:53\u201360."},{"key":"B98","series-title":"J Urol","first-page":"41","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo A","year":"2016","unstructured":"Yokomizo A, Kanimoto Y, Okamura T,  Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer. J Urol 2016;195:41\u201346."},{"key":"B99","series-title":"J Urol","first-page":"538","article-title":"Bacillus Calmette-Gu\u00e9rin manufacturing and SWOG S1602 Intergroup clinical trial","volume":"197","author":"Meeks JJ","year":"2017","unstructured":"Meeks JJ, Lerner SP, Svatek RS. Bacillus Calmette-Gu\u00e9rin manufacturing and SWOG S1602 Intergroup clinical trial. J Urol 2017;197:538\u2013540."},{"key":"B100","series-title":"Eur Urol Focus","first-page":"522","article-title":"Background and update for S1602 \u201dA phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek RS","year":"2018","unstructured":"Svatek RS, Tangen C, Delacroix S,  Background and update for S1602 \u201dA phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer. Eur Urol Focus 2018;4:522\u2013524."},{"key":"B101","series-title":"J Clin Oncol","first-page":"3578","article-title":"TAR-200 for bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand S","year":"2025","unstructured":"Daneshmand S, Van der Heijden MS, Jacob JM,  TAR-200 for bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. J Clin Oncol 2025;43:3578\u20133588."},{"key":"B102","series-title":"Lancet Oncol","first-page":"107","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian SA","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR,  Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021;22:107\u2013117."},{"key":"B103","series-title":"J Urol","first-page":"e296 Abstract MP16-01","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial","volume":"206","author":"Schuckman AK","year":"2021","unstructured":"Schuckman AK, Lotan Y, Boorjian SA,  Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial. J Urol 2021;206:e296 Abstract MP16-01."},{"key":"B104","series-title":"J Urol","first-page":"Abstract MP16-02","article-title":"Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the Ta\/T1 cohort [abstract]","author":"Lotan Y","year":"2021","unstructured":"Lotan Y, Schuckman AK, Boorjian SA,  Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the Ta\/T1 cohort [abstract]. J Urol 2021.Abstract MP16-02."},{"key":"B105","series-title":"NEJM Evid","first-page":"EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie K","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E,  IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid 2023;2:EVIDoa2200167."},{"key":"B106","series-title":"Urol Pract","first-page":"367","article-title":"Quality of life in the phase 2\/3 trial of N-803 plus bacillus Calmette-Gu\u00e9rin in bacillus Calmette-Gu\u00e9rin\u2013unresponsive nonmuscle-invasive bladder cancer","volume":"11","author":"Chamie K","year":"2024","unstructured":"Chamie K, Chang SS, Kramolowsky EV,  Quality of life in the phase 2\/3 trial of N-803 plus bacillus Calmette-Gu\u00e9rin in bacillus Calmette-Gu\u00e9rin\u2013unresponsive nonmuscle-invasive bladder cancer. Urol Pract 2024;11:367\u2013375."},{"key":"B107","series-title":"Lancet Oncol","first-page":"919","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar AV","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS,  Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919\u2013930."},{"key":"B108","series-title":"J Clin Oncol","first-page":"Abstract 451","article-title":"Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin: extended follow-up of KEYNOTE-057 cohort A","volume":"39","author":"Balar AV","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS,  Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin: extended follow-up of KEYNOTE-057 cohort A. J Clin Oncol 2021;39(Suppl):Abstract 451."},{"key":"B109","series-title":"Lancet Oncol","first-page":"720","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi A","year":"2024","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM,  Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2024;25:720\u2013730."},{"key":"B110","series-title":"J Clin Oncol","first-page":"Abstract LBA442","article-title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial","volume":"41","author":"Necchi A","year":"2023","unstructured":"Necchi A, Roumigui\u00e9 M, Esen AA,  Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial. J Clin Oncol 2023;41:Abstract LBA442."},{"key":"B111","series-title":"J Urol","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang SS","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R,  Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 2016;196:1021\u20131029."},{"key":"B112","series-title":"J Urol","first-page":"505","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch CR","year":"2020","unstructured":"Ritch CR, Velasquez MC, Kwon D,  Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol 2020;203:505\u2013511."},{"key":"B113","series-title":"Eur Urol Oncol","first-page":"505","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan WS","year":"2022","unstructured":"Tan WS, Steinberg G, Witjes JA,  Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505\u2013516."},{"key":"B114","series-title":"Curr Urol Rep","first-page":"109","article-title":"Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer","volume":"13","author":"Ramirez-Backhaus M","year":"2012","unstructured":"Ramirez-Backhaus M, Dominguez-Escrig J, Collado A,  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep 2012;13:109\u2013114."},{"key":"B115","series-title":"J Urol","first-page":"1641","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik RT","year":"2006","unstructured":"Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641\u20131644."},{"key":"B116","series-title":"Int J Clin Oncol","first-page":"698","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu A","year":"2020","unstructured":"Eroglu A, Ekin RG, Koc G, Divrik RT. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol 2020;25:698\u2013704."},{"key":"B117","series-title":"J Urol","first-page":"433","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study","volume":"170","author":"Grimm MO","year":"2003","unstructured":"Grimm MO, Steinhoff C, Simon X,  Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433\u2013437."},{"key":"B118","series-title":"J Urol","first-page":"74","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr HW.","year":"1999","unstructured":"Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74\u201376."},{"key":"B119","series-title":"Cancer Treat Res Commun","first-page":"100369","article-title":"Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis","volume":"27","author":"Petrelli F","year":"2021","unstructured":"Petrelli F, Giannatempo P, Maccagnano C,  Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis. Cancer Treat Res Commun 2021;27:100369."},{"key":"B120","series-title":"Eur Urol Focus","first-page":"447","article-title":"Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina E","year":"2022","unstructured":"Laukhtina E, Abufaraj M, Al-Ani A,  Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus 2022;8:447\u2013456."},{"key":"B121","series-title":"Anticancer Res","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek M","year":"2001","unstructured":"Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21:765\u2013769."},{"key":"B122","series-title":"J Clin Epidemiol","first-page":"676","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek M","year":"2000","unstructured":"Huncharek M, Geschwind JF, Witherspoon B,  Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676\u2013680."},{"key":"B123","series-title":"Bladder Cancer","first-page":"193","article-title":"CIS of the bladder: significance and implications for therapy","volume":"5","author":"Mirabal JR","year":"2019","unstructured":"Mirabal JR, Taylor JA, Lerner SP. CIS of the bladder: significance and implications for therapy. Bladder Cancer 2019;5:193\u2013204."},{"key":"B124","series-title":"J Clin Oncol","first-page":"1935","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat AM","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A,  Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:1935\u20131944."},{"key":"B125","series-title":"Eur Urol","first-page":"34","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumiguie M","year":"2022","unstructured":"Roumiguie M, Kamat AM, Bivalacqua TJ,  International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol 2022;82:34\u201346."},{"key":"B126","series-title":"J Urol","first-page":"1296","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr HW","year":"2001","unstructured":"Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296\u20131299."},{"key":"B127","series-title":"BJU Int","first-page":"11","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari A","year":"2019","unstructured":"Mari A, Kimura S, Foerster B,  A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123:11\u201321."},{"key":"B128","series-title":"J Clin Oncol","first-page":"202","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study","volume":"39","author":"Catto JWF","year":"2021","unstructured":"Catto JWF, Gordon K, Collinson M,  Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study. J Clin Oncol 2021;39:202\u2013214."},{"key":"B129","series-title":"Nat Med","first-page":"2806","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore ND","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J,  Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 2025;31:2806\u20132814."},{"key":"B130","series-title":"Lancet","first-page":"2221","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis M","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H,  Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 2025;406:2221\u20132234."},{"key":"B131","series-title":"Cancers (Basel)","first-page":"636","article-title":"Therapeutic advances in bladder preservation for BCG-unresponsive non-muscle invasive bladder cancer","volume":"17","author":"Lange A","year":"2025","unstructured":"Lange A, Madiraju S, Petros FG. Therapeutic advances in bladder preservation for BCG-unresponsive non-muscle invasive bladder cancer. Cancers (Basel) 2025;17:636."},{"key":"B132","series-title":"Eur Urol","first-page":"366","article-title":"Challenging the paradigm of \u201cBCG-unresponsive\u201d bladder cancer: does additional bacillus Calmette-Guerin have an effect?","volume":"86","author":"Myers AA","year":"2024","unstructured":"Myers AA, Tan WS, Grajales V,  Challenging the paradigm of \u201cBCG-unresponsive\u201d bladder cancer: does additional bacillus Calmette-Guerin have an effect? Eur Urol 2024;86:366\u2013368."},{"key":"B133","series-title":"Ann Intern Med","first-page":"922","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis","volume":"163","author":"Chou R","year":"2015","unstructured":"Chou R, Gore JL, Buckley D,  Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med 2015;163:922\u2013931."},{"key":"B134","series-title":"Oncol Lett","first-page":"2181","article-title":"Bladder and vaginal transitional cell carcinoma: a case report","volume":"12","author":"Aoun F","year":"2016","unstructured":"Aoun F, Kourie HR, El Rassy E, van Velthoven R. Bladder and vaginal transitional cell carcinoma: a case report. Oncol Lett 2016;12:2181\u20132183."},{"key":"B135","series-title":"Diagn Pathol","first-page":"9","article-title":"Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary","volume":"14","author":"Koyanagi Y","year":"2019","unstructured":"Koyanagi Y, Kubo C, Nagata S,  Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary. Diagn Pathol 2019;14:9."},{"key":"B136","series-title":"Am J Surg Pathol","first-page":"1058","article-title":"Urothelial carcinoma involving the gynecologic tract: a morphologic and immunohistochemical study of 6 cases","volume":"36","author":"Reyes MC","year":"2012","unstructured":"Reyes MC, Park KJ, Lin O,  Urothelial carcinoma involving the gynecologic tract: a morphologic and immunohistochemical study of 6 cases. Am J Surg Pathol 2012;36:1058\u20131065."},{"key":"B137","series-title":"J Urol","first-page":"1751","article-title":"The management of clinically unconfirmed positive urinary cytology","volume":"150","author":"Schwalb DM","year":"1993","unstructured":"Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol 1993;150:1751\u20131756."},{"key":"B1","series-title":"CA Cancer J Clin","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS,  Cancer statistics, 2026. CA Cancer J Clin 2026;76:e70043."},{"key":"B2","article-title":"Cancer stat facts: bladder cancer","unstructured":"National Cancer Institute. Cancer stat facts: bladder cancer. Accessed October 31, 2025. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"B3","series-title":"Am Fam Physician","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge KC","year":"2017","unstructured":"DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician 2017;96:507\u2013514."},{"key":"B4","series-title":"Medicine (Baltimore)","first-page":"e8588","article-title":"Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies","volume":"96","author":"Xu Y","year":"2017","unstructured":"Xu Y, Huo R, Chen X, Yu X. Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 2017;96:e8588."},{"key":"B5","series-title":"Eur Urol","first-page":"96","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni S","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I,  Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71:96\u2013108."},{"key":"B6","series-title":"Urol Oncol","first-page":"199","article-title":"Bladder cancer risk from occupational and environmental exposures","volume":"30","author":"Kiriluk KJ","year":"2012","unstructured":"Kiriluk KJ, Prasad SM, Patel AR,  Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012;30:199\u2013211."},{"key":"B7","series-title":"J Clin Oncol","first-page":"406","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo MI","year":"2020","unstructured":"Carlo MI, Ravichandran V, Srinavasan P,  Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol 2020;38:406\u2013414."},{"key":"B8","series-title":"Urol Oncol","first-page":"25.e21","article-title":"Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study","volume":"32","author":"Welty CJ","year":"2014","unstructured":"Welty CJ, Wright JL, Hotaling JM,  Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. Urol Oncol 2014;32:25.e21\u201325."},{"key":"B9","series-title":"J Med Genet","first-page":"464","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post RS","year":"2010","unstructured":"van der Post RS, Kiemeney LA, Ligtenberg MJ,  Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010;47:464\u2013470."},{"key":"B10","series-title":"JAMA","first-page":"1880","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing EM","year":"2018","unstructured":"Messing EM, Tangen CM, Lerner SP,  Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 2018;319:1880\u20131888."},{"key":"B11","series-title":"Eur Urol","first-page":"226","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter J","year":"2018","unstructured":"Bosschieter J, Nieuwenhuijzen JA, van Ginkel T,  Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol 2018;73:226\u2013232."},{"key":"B12","series-title":"Eur Urol","first-page":"231","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?","volume":"69","author":"Sylvester RJ","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S,  Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016;69:231\u2013244."},{"key":"B13","series-title":"Int J Urol","first-page":"631","article-title":"Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: are they necessary?","volume":"10","author":"Fujimoto N","year":"2003","unstructured":"Fujimoto N, Harada S, Terado M,  Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: are they necessary? Int J Urol 2003;10:631\u2013635."},{"key":"B14","series-title":"BJU Int","first-page":"E41","article-title":"The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS)","volume":"110","author":"Gudjonsson S","year":"2012","unstructured":"Gudjonsson S, Blackberg M, Chebil G,  The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS). BJU Int 2012;110:E41\u201345."},{"key":"B15","series-title":"BJU Int","first-page":"1499","article-title":"Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?","volume":"106","author":"Herr HW","year":"2010","unstructured":"Herr HW, Al-Ahmadie H, Dalbagni G, Reuter VE. Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity? BJU Int 2010;106:1499\u20131501."},{"key":"B16","series-title":"BMC Urol","first-page":"12","article-title":"Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study","volume":"10","author":"Matsushima M","year":"2010","unstructured":"Matsushima M, Kikuchi E, Hasegawa M,  Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study. BMC Urol 2010;10:12."},{"key":"B17","series-title":"AJCC Cancer Staging Manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene F,  eds. AJCC Cancer Staging Manual, 8th ed. New York: Springer International Publishing; 2017."},{"key":"B18","series-title":"Rev Urol","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin E","year":"2008","unstructured":"Pasin E, Josephson DY, Mitra AP,  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008;10:31\u201343."},{"key":"B19","series-title":"Hum Pathol","first-page":"95","article-title":"Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion","volume":"44","author":"Brimo F","year":"2013","unstructured":"Brimo F, Wu C, Zeizafoun N,  Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol 2013;44:95\u2013102."},{"key":"B20","series-title":"Ann Diagn Pathol","first-page":"49","article-title":"Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence","volume":"18","author":"Hu Z","year":"2014","unstructured":"Hu Z, Mudaliar K, Quek ML,  Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Ann Diagn Pathol 2014;18:49\u201352."},{"key":"B21","series-title":"Eur Urol","first-page":"378","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn BW","year":"2012","unstructured":"van Rhijn BW, van der Kwast TH, Alkhateeb SS,  A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378\u2013384."},{"key":"B22","series-title":"Eur Urol","first-page":"466","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester RJ","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W,  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466\u2013465; discussion 475\u2013467."},{"key":"B23","series-title":"AJCC Cancer Staging Manual","author":"Edge SB","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC,  AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010."},{"key":"B24","series-title":"J Urol","first-page":"135","article-title":"Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy","volume":"171","author":"Schmidbauer J","year":"2004","unstructured":"Schmidbauer J, Witjes F, Schmeller N,  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135\u2013138."},{"key":"B25","series-title":"J Urol","first-page":"862","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study","volume":"174","author":"Jocham D","year":"2005","unstructured":"Jocham D, Witjes F, Wagner S,  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862\u2013866."},{"key":"B26","series-title":"J Urol","first-page":"62","article-title":"A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer","volume":"178","author":"Grossman HB","year":"2007","unstructured":"Grossman HB, Gomella L, Fradet Y,  A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62\u201367."},{"key":"B27","series-title":"J Urol","first-page":"68","article-title":"A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study","volume":"178","author":"Fradet Y","year":"2007","unstructured":"Fradet Y, Grossman HB, Gomella L,  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68\u201373."},{"key":"B28","series-title":"J Urol","first-page":"1907","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl A","year":"2010","unstructured":"Stenzl A, Burger M, Fradet Y,  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907\u20131913."},{"key":"B29","series-title":"BJU Int","first-page":"E297","article-title":"Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study","volume":"108","author":"Hermann GG","year":"2011","unstructured":"Hermann GG, Mogensen K, Carlsson S,  Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta\/T1 patients: a randomized two-centre study. BJU Int 2011;108:E297\u2013303."},{"key":"B30","series-title":"PLoS One","first-page":"e74142","article-title":"Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials","volume":"8","author":"Yuan H","year":"2013","unstructured":"Yuan H, Qiu J, Liu L,  Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One 2013;8:e74142."},{"key":"B31","series-title":"Eur Urol","first-page":"846","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger M","year":"2013","unstructured":"Burger M, Grossman HB, Droller M,  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846\u2013854."},{"key":"B32","series-title":"Eur Urol","first-page":"624","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink M","year":"2013","unstructured":"Rink M, Babjuk M, Catto JW,  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 2013;64:624\u2013638."},{"key":"B33","series-title":"Bladder Cancer","first-page":"273","article-title":"The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis","volume":"2","author":"Kamat AM","year":"2016","unstructured":"Kamat AM, Cookson M, Witjes JA,  The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer 2016;2:273\u2013278."},{"key":"B34","series-title":"Urology","first-page":"658","article-title":"Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer","volume":"76","author":"Cauberg EC","year":"2010","unstructured":"Cauberg EC, Kloen S, Visser M,  Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology 2010;76:658\u2013663."},{"key":"B35","series-title":"Urol Oncol","first-page":"475","article-title":"Applying narrow-band imaging in complement with white-light imaging cystoscopy in the detection of urothelial carcinoma of the bladder","volume":"31","author":"Chen G","year":"2013","unstructured":"Chen G, Wang B, Li H,  Applying narrow-band imaging in complement with white-light imaging cystoscopy in the detection of urothelial carcinoma of the bladder. Urol Oncol 2013;31:475\u2013479."},{"key":"B36","series-title":"Ther Adv Urol","first-page":"211","article-title":"Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach","volume":"4","author":"Geavlete B","year":"2012","unstructured":"Geavlete B, Jecu M, Multescu R, Geavlete P. Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Ther Adv Urol 2012;4:211\u2013217."},{"key":"B37","series-title":"Int Urol Nephrol","first-page":"451","article-title":"Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a \u201csecond look\u201d matters?","volume":"44","author":"Shen YJ","year":"2012","unstructured":"Shen YJ, Zhu YP, Ye DW,  Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a \u201csecond look\u201d matters? Int Urol Nephrol 2012;44:451\u2013457."},{"key":"B38","series-title":"J Endourol","first-page":"1807","article-title":"Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer","volume":"24","author":"Tatsugami K","year":"2010","unstructured":"Tatsugami K, Kuroiwa K, Kamoto T,  Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol 2010;24:1807\u20131811."},{"key":"B39","series-title":"Eur Urol","first-page":"908","article-title":"A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence","volume":"61","author":"Naselli A","year":"2012","unstructured":"Naselli A, Introini C, Timossi L,  A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol 2012;61:908\u2013913."},{"key":"B40","series-title":"Eur Urol","first-page":"506","article-title":"The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results","volume":"70","author":"Naito S","year":"2016","unstructured":"Naito S, Algaba F, Babjuk M,  The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 2016;70:506\u2013515."},{"key":"B41","series-title":"PLoS One","first-page":"e0170819","article-title":"A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer","volume":"12","author":"Xiong Y","year":"2017","unstructured":"Xiong Y, Li J, Ma S,  A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One 2017;12:e0170819."},{"key":"B42","series-title":"Oncotarget","first-page":"23880","article-title":"Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Kang W","year":"2017","unstructured":"Kang W, Cui Z, Chen Q,  Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis. Oncotarget 2017;8:23880\u201323890."},{"key":"B43","series-title":"BJU Int","first-page":"1111","article-title":"A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences","volume":"102","author":"Herr HW","year":"2008","unstructured":"Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102:1111\u20131114."},{"key":"B44","series-title":"Pathologica","first-page":"32","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"115","author":"Raspollini MR","year":"2022","unstructured":"Raspollini MR, Comperat EM, Lopez-Beltran A,  News in the classification of WHO 2022 bladder tumors. Pathologica 2022;115:32\u201340."},{"key":"B45","series-title":"Eur Urol","first-page":"458","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2013part a: renal, penile, and testicular tumours","volume":"82","author":"Moch H","year":"2022","unstructured":"Moch H, Amin MB, Berney DM,  The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2013part a: renal, penile, and testicular tumours. Eur Urol 2022;82:458\u2013468."},{"key":"B46","series-title":"Eur Urol","first-page":"469","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2013part b: prostate and urinary tract tumors","volume":"82","author":"Netto GJ","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM,  The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2013part b: prostate and urinary tract tumors. Eur Urol 2022;82:469\u2013482."},{"key":"B47","series-title":"Urol Oncol","first-page":"15","article-title":"The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis","volume":"39","author":"Kardoust Parizi M","year":"2021","unstructured":"Kardoust Parizi M, Margulis V, Compe Rat E, Shariat SF. The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis. Urol Oncol 2021;39:15\u201333."},{"key":"B48","series-title":"J Urol","first-page":"1129","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori K","year":"2020","unstructured":"Mori K, Abufaraj M, Mostafaei H,  A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2020;204:1129\u20131140."},{"key":"B49","series-title":"Eur Urol Oncol","first-page":"625","article-title":"What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review","volume":"2","author":"Veskimae E","year":"2019","unstructured":"Veskimae E, Espinos EL, Bruins HM,  What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol 2019;2:625\u2013642."},{"key":"B50","series-title":"Semin Oncol","first-page":"619","article-title":"Urachal adenocarcinoma: a clinician's guide for treatment","volume":"39","author":"Siefker-Radtke A.","year":"2012","unstructured":"Siefker-Radtke A. Urachal adenocarcinoma: a clinician's guide for treatment. Semin Oncol 2012;39:619\u2013624."},{"key":"B51","series-title":"Cochrane Database Syst Rev","first-page":"CD009294","article-title":"Intravesical gemcitabine for non- muscle invasive bladder cancer","volume":"1","author":"Jones G","year":"2012","unstructured":"Jones G, Cleves A, Wilt TJ,  Intravesical gemcitabine for non- muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:CD009294."},{"key":"B52","series-title":"J Urol","first-page":"86","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester RJ","year":"2005","unstructured":"Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86\u201391; discussion 91\u201392."},{"key":"B53","series-title":"Cochrane Database Syst Rev","first-page":"CD009294","article-title":"Intravesical gemcitabine for non- muscle invasive bladder cancer","volume":"6","author":"Han MA","year":"2021","unstructured":"Han MA, Maisch P, Jung JH,  Intravesical gemcitabine for non- muscle invasive bladder cancer. Cochrane Database Syst Rev 2021;6:CD009294."},{"key":"B54","series-title":"BMC Urol","first-page":"97","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta- analysis of randomized controlled trial","volume":"20","author":"Li R","year":"2020","unstructured":"Li R, Li Y, Song J,  Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta- analysis of randomized controlled trial. BMC Urol 2020;20:97."},{"key":"B55","series-title":"Eur Urol","first-page":"516","article-title":"Bladder-sparing therapy for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection","volume":"86","author":"Li R","year":"2024","unstructured":"Li R, Hensley PJ, Gupta S,  Bladder-sparing therapy for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection. Eur Urol 2024;86:516\u2013527."},{"key":"B56","series-title":"Urol Oncol","first-page":"9.e1","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Gu\u00e9rin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg RL","year":"2022","unstructured":"Steinberg RL, Packiam VT, Thomas LJ,  Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Gu\u00e9rin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol 2022;40:9.e1\u20137."},{"key":"B57","series-title":"J Urol","first-page":"902","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg RL","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N,  Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902\u2013909."},{"key":"B58","series-title":"J Urol","first-page":"589","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree IM","year":"2022","unstructured":"McElree IM, Steinberg RL, Martin AC,  Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer. J Urol 2022;208:589\u2013599."},{"key":"B59","series-title":"JAMA Netw Open","first-page":"e230849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree IM","year":"2023","unstructured":"McElree IM, Steinberg RL, Mott SL,  Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer. JAMA Netw Open 2023;6:e230849."},{"key":"B60","series-title":"J Urol","first-page":"180","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales A","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180\u2013183."},{"key":"B61","series-title":"J Urol","first-page":"90","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle A","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90\u201395."},{"key":"B62","series-title":"Urology","first-page":"1216","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han RF","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216\u20131223."},{"key":"B63","series-title":"BJU Int","first-page":"209","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley MD","year":"2001","unstructured":"Shelley MD, Kynaston H, Court J,  A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209\u2013216."},{"key":"B64","series-title":"BJU Int","first-page":"485","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley MD","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J,  Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485\u2013490."},{"key":"B65","series-title":"Eur Urol","first-page":"247","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom PU","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE,  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247\u2013256."},{"key":"B66","series-title":"J Oncol Pract","first-page":"92","article-title":"Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer BA","year":"2013","unstructured":"Spencer BA, McBride RB, Hershman DL,  Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract 2013;9:92\u201398."},{"key":"B67","series-title":"Eur Urol","first-page":"260","article-title":"Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up","volume":"56","author":"Jarvinen R","year":"2009","unstructured":"Jarvinen R, Kaasinen E, Sankila A,  Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 2009;56:260\u2013265."},{"key":"B68","series-title":"Cochrane Database Syst Rev","first-page":"CD011935","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt S","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B,  Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2020;1:CD011935."},{"key":"B69","series-title":"J Urol","first-page":"857","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero P","year":"2013","unstructured":"Gontero P, Oderda M, Mehnert A,  The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 2013;190:857\u2013862."},{"key":"B70","series-title":"Eur Urol","first-page":"766","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester RJ","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ,  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766\u2013773."},{"key":"B71","series-title":"Eur Urol","first-page":"25","article-title":"Bacillus Calmette-","volume":"57","author":"Duchek M","year":"2010","unstructured":"Duchek M, Johansson R, Jahnson S,  Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 2010;57:25\u201331."},{"key":"B72","series-title":"J Urol","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm DL","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD,  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124\u20131129."},{"key":"B73","series-title":"Eur Urol","first-page":"579","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence","volume":"64","author":"Ehdaie B","year":"2013","unstructured":"Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013;64:579\u2013585."},{"key":"B74","series-title":"Eur Urol","first-page":"462","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette- Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens J","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R,  Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette- Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462\u2013472."},{"key":"B75","series-title":"Urology","first-page":"682","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle A","year":"2004","unstructured":"Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682\u2013686; discussion 686\u2013687."},{"key":"B76","series-title":"J Urol","first-page":"1964","article-title":"Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester RJ","year":"2002","unstructured":"Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964\u20131970."},{"key":"B77","article-title":"Prescribing information for BCG live, for intravesical use","year":"2009","unstructured":"Prescribing information for BCG live, for intravesical use. 2009. Accessed February 8, 2024. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM163039.pdf"},{"key":"B78","series-title":"Eur Urol","first-page":"429","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden AP","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W,  Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429\u2013434."},{"key":"B79","series-title":"J Urol","first-page":"935","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel M","year":"2006","unstructured":"Colombel M, Saint F, Chopin D,  The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935\u2013939."},{"key":"B80","series-title":"BJU Int","first-page":"633","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano R","year":"2009","unstructured":"Damiano R, De Sio M, Quarto G,  Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity? BJU Int 2009;104:633\u2013639."},{"key":"B81","series-title":"Eur Urol","first-page":"69","article-title":"Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi M","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R,  Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69\u201376."},{"key":"B82","series-title":"J Urol","first-page":"63","article-title":"Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations","volume":"163","author":"Lebret T","year":"2000","unstructured":"Lebret T, Bohin D, Kassardjian Z,  Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 2000;163:63\u201367."},{"key":"B83","series-title":"J Urol","first-page":"1242","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro JA","year":"2005","unstructured":"Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E,  Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242\u20131247."},{"key":"B84","series-title":"Jpn J Clin Oncol","first-page":"395","article-title":"Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG","volume":"35","author":"Mugiya S","year":"2005","unstructured":"Mugiya S, Ozono S, Nagata M,  Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG. Jpn J Clin Oncol 2005;35:395\u2013399."},{"key":"B85","series-title":"Eur Urol","first-page":"690","article-title":"Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial \u201cNIMBUS","volume":"78","author":"Grimm MO","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M,  Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial \u201cNIMBUS. Eur Urol 2020;78:690\u2013698."},{"key":"B86","series-title":"Eur Urol Focus","first-page":"481","article-title":"Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari J","year":"2018","unstructured":"Bandari J, Maganty A, MacLeod LC, Davies BJ. Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Gu\u00e9rin. Eur Urol Focus 2018;4:481\u2013484."},{"key":"B87","article-title":"BCG shortage notice","unstructured":"American Urological Association. BCG shortage notice. Accessed February 8, 2024. Available at: https:\/\/www.auanet.org\/bcg-shortage-notice"},{"key":"B88","series-title":"Bladder Cancer","first-page":"293","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar N","year":"2017","unstructured":"Milbar N, Kates M, Chappidi MR,  Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 2017;3:293\u2013303."},{"key":"B89","series-title":"Cancer","first-page":"1893","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non- muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo G","year":"2010","unstructured":"Di Lorenzo G, Perdona S, Damiano R,  Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non- muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010;116:1893\u20131900."},{"key":"B90","series-title":"Eur Urol","first-page":"1123","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich MG","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H,  Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52:1123\u20131129."},{"key":"B91","series-title":"J Urol","first-page":"1189","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou R","year":"2017","unstructured":"Chou R, Selph S, Buckley DI,  Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017;197:1189\u20131199."},{"key":"B92","series-title":"J Urol","first-page":"476","article-title":"Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial","volume":"166","author":"van der Meijden AP","year":"2001","unstructured":"van der Meijden AP, Brausi M, Zambon V,  Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001;166:476\u2013481."},{"key":"B93","series-title":"J Urol","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg G","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S,  Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761\u2013767."},{"key":"B94","series-title":"World J Urol","first-page":"331","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow LJ","year":"2009","unstructured":"Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 2009;27:331\u2013335."},{"key":"B95","series-title":"Urol Oncol","first-page":"510","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer BN","year":"2010","unstructured":"Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 2010;28:510\u2013514."},{"key":"B96","series-title":"Eur Urol","first-page":"597","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen Z","year":"2018","unstructured":"Klaassen Z, Kamat AM, Kassouf W,  Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol 2018;74:597\u2013608."},{"key":"B97","series-title":"Int J Urol","first-page":"53","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister C","year":"2015","unstructured":"Pfister C, Kerkeni W, Rigaud J,  Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study. Int J Urol 2015;22:53\u201360."},{"key":"B98","series-title":"J Urol","first-page":"41","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo A","year":"2016","unstructured":"Yokomizo A, Kanimoto Y, Okamura T,  Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer. J Urol 2016;195:41\u201346."},{"key":"B99","series-title":"J Urol","first-page":"538","article-title":"Bacillus Calmette-Gu\u00e9rin manufacturing and SWOG S1602 Intergroup clinical trial","volume":"197","author":"Meeks JJ","year":"2017","unstructured":"Meeks JJ, Lerner SP, Svatek RS. Bacillus Calmette-Gu\u00e9rin manufacturing and SWOG S1602 Intergroup clinical trial. J Urol 2017;197:538\u2013540."},{"key":"B100","series-title":"Eur Urol Focus","first-page":"522","article-title":"Background and update for S1602 \u201dA phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek RS","year":"2018","unstructured":"Svatek RS, Tangen C, Delacroix S,  Background and update for S1602 \u201dA phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer. Eur Urol Focus 2018;4:522\u2013524."},{"key":"B101","series-title":"J Clin Oncol","first-page":"3578","article-title":"TAR-200 for bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand S","year":"2025","unstructured":"Daneshmand S, Van der Heijden MS, Jacob JM,  TAR-200 for bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. J Clin Oncol 2025;43:3578\u20133588."},{"key":"B102","series-title":"Lancet Oncol","first-page":"107","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian SA","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR,  Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021;22:107\u2013117."},{"key":"B103","series-title":"J Urol","first-page":"e296 Abstract MP16-01","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial","volume":"206","author":"Schuckman AK","year":"2021","unstructured":"Schuckman AK, Lotan Y, Boorjian SA,  Efficacy of intravesical nadofaragene firadenovec for patients with carcinoma in situ (CIS), BCG-unresponsive non-muscle invasive bladder cancer (NMIBC): longer-term follow-up from the phase III trial. J Urol 2021;206:e296 Abstract MP16-01."},{"key":"B104","series-title":"J Urol","first-page":"Abstract MP16-02","article-title":"Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the Ta\/T1 cohort [abstract]","author":"Lotan Y","year":"2021","unstructured":"Lotan Y, Schuckman AK, Boorjian SA,  Phase III trial of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive, non-muscle invasive bladder cancer: two year follow-up in the Ta\/T1 cohort [abstract]. J Urol 2021.Abstract MP16-02."},{"key":"B105","series-title":"NEJM Evid","first-page":"EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie K","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E,  IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid 2023;2:EVIDoa2200167."},{"key":"B106","series-title":"Urol Pract","first-page":"367","article-title":"Quality of life in the phase 2\/3 trial of N-803 plus bacillus Calmette-Gu\u00e9rin in bacillus Calmette-Gu\u00e9rin\u2013unresponsive nonmuscle-invasive bladder cancer","volume":"11","author":"Chamie K","year":"2024","unstructured":"Chamie K, Chang SS, Kramolowsky EV,  Quality of life in the phase 2\/3 trial of N-803 plus bacillus Calmette-Gu\u00e9rin in bacillus Calmette-Gu\u00e9rin\u2013unresponsive nonmuscle-invasive bladder cancer. Urol Pract 2024;11:367\u2013375."},{"key":"B107","series-title":"Lancet Oncol","first-page":"919","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar AV","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS,  Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919\u2013930."},{"key":"B108","series-title":"J Clin Oncol","first-page":"Abstract 451","article-title":"Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin: extended follow-up of KEYNOTE-057 cohort A","volume":"39","author":"Balar AV","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS,  Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin: extended follow-up of KEYNOTE-057 cohort A. J Clin Oncol 2021;39(Suppl):Abstract 451."},{"key":"B109","series-title":"Lancet Oncol","first-page":"720","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi A","year":"2024","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM,  Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2024;25:720\u2013730."},{"key":"B110","series-title":"J Clin Oncol","first-page":"Abstract LBA442","article-title":"Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial","volume":"41","author":"Necchi A","year":"2023","unstructured":"Necchi A, Roumigui\u00e9 M, Esen AA,  Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin (BCG): results from cohort B of the phase 2 KEYNOTE-057 trial. J Clin Oncol 2023;41:Abstract LBA442."},{"key":"B111","series-title":"J Urol","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang SS","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R,  Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 2016;196:1021\u20131029."},{"key":"B112","series-title":"J Urol","first-page":"505","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch CR","year":"2020","unstructured":"Ritch CR, Velasquez MC, Kwon D,  Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol 2020;203:505\u2013511."},{"key":"B113","series-title":"Eur Urol Oncol","first-page":"505","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan WS","year":"2022","unstructured":"Tan WS, Steinberg G, Witjes JA,  Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505\u2013516."},{"key":"B114","series-title":"Curr Urol Rep","first-page":"109","article-title":"Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer","volume":"13","author":"Ramirez-Backhaus M","year":"2012","unstructured":"Ramirez-Backhaus M, Dominguez-Escrig J, Collado A,  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep 2012;13:109\u2013114."},{"key":"B115","series-title":"J Urol","first-page":"1641","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik RT","year":"2006","unstructured":"Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641\u20131644."},{"key":"B116","series-title":"Int J Clin Oncol","first-page":"698","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu A","year":"2020","unstructured":"Eroglu A, Ekin RG, Koc G, Divrik RT. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol 2020;25:698\u2013704."},{"key":"B117","series-title":"J Urol","first-page":"433","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study","volume":"170","author":"Grimm MO","year":"2003","unstructured":"Grimm MO, Steinhoff C, Simon X,  Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433\u2013437."},{"key":"B118","series-title":"J Urol","first-page":"74","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr HW.","year":"1999","unstructured":"Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74\u201376."},{"key":"B119","series-title":"Cancer Treat Res Commun","first-page":"100369","article-title":"Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis","volume":"27","author":"Petrelli F","year":"2021","unstructured":"Petrelli F, Giannatempo P, Maccagnano C,  Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis. Cancer Treat Res Commun 2021;27:100369."},{"key":"B120","series-title":"Eur Urol Focus","first-page":"447","article-title":"Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina E","year":"2022","unstructured":"Laukhtina E, Abufaraj M, Al-Ani A,  Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus 2022;8:447\u2013456."},{"key":"B121","series-title":"Anticancer Res","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek M","year":"2001","unstructured":"Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21:765\u2013769."},{"key":"B122","series-title":"J Clin Epidemiol","first-page":"676","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek M","year":"2000","unstructured":"Huncharek M, Geschwind JF, Witherspoon B,  Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000;53:676\u2013680."},{"key":"B123","series-title":"Bladder Cancer","first-page":"193","article-title":"CIS of the bladder: significance and implications for therapy","volume":"5","author":"Mirabal JR","year":"2019","unstructured":"Mirabal JR, Taylor JA, Lerner SP. CIS of the bladder: significance and implications for therapy. Bladder Cancer 2019;5:193\u2013204."},{"key":"B124","series-title":"J Clin Oncol","first-page":"1935","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat AM","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A,  Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:1935\u20131944."},{"key":"B125","series-title":"Eur Urol","first-page":"34","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumiguie M","year":"2022","unstructured":"Roumiguie M, Kamat AM, Bivalacqua TJ,  International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol 2022;82:34\u201346."},{"key":"B126","series-title":"J Urol","first-page":"1296","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr HW","year":"2001","unstructured":"Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296\u20131299."},{"key":"B127","series-title":"BJU Int","first-page":"11","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari A","year":"2019","unstructured":"Mari A, Kimura S, Foerster B,  A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 2019;123:11\u201321."},{"key":"B128","series-title":"J Clin Oncol","first-page":"202","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study","volume":"39","author":"Catto JWF","year":"2021","unstructured":"Catto JWF, Gordon K, Collinson M,  Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study. J Clin Oncol 2021;39:202\u2013214."},{"key":"B129","series-title":"Nat Med","first-page":"2806","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore ND","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J,  Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 2025;31:2806\u20132814."},{"key":"B130","series-title":"Lancet","first-page":"2221","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis M","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H,  Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 2025;406:2221\u20132234."},{"key":"B131","series-title":"Cancers (Basel)","first-page":"636","article-title":"Therapeutic advances in bladder preservation for BCG-unresponsive non-muscle invasive bladder cancer","volume":"17","author":"Lange A","year":"2025","unstructured":"Lange A, Madiraju S, Petros FG. Therapeutic advances in bladder preservation for BCG-unresponsive non-muscle invasive bladder cancer. Cancers (Basel) 2025;17:636."},{"key":"B132","series-title":"Eur Urol","first-page":"366","article-title":"Challenging the paradigm of \u201cBCG-unresponsive\u201d bladder cancer: does additional bacillus Calmette-Guerin have an effect?","volume":"86","author":"Myers AA","year":"2024","unstructured":"Myers AA, Tan WS, Grajales V,  Challenging the paradigm of \u201cBCG-unresponsive\u201d bladder cancer: does additional bacillus Calmette-Guerin have an effect? Eur Urol 2024;86:366\u2013368."},{"key":"B133","series-title":"Ann Intern Med","first-page":"922","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis","volume":"163","author":"Chou R","year":"2015","unstructured":"Chou R, Gore JL, Buckley D,  Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med 2015;163:922\u2013931."},{"key":"B134","series-title":"Oncol Lett","first-page":"2181","article-title":"Bladder and vaginal transitional cell carcinoma: a case report","volume":"12","author":"Aoun F","year":"2016","unstructured":"Aoun F, Kourie HR, El Rassy E, van Velthoven R. Bladder and vaginal transitional cell carcinoma: a case report. Oncol Lett 2016;12:2181\u20132183."},{"key":"B135","series-title":"Diagn Pathol","first-page":"9","article-title":"Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary","volume":"14","author":"Koyanagi Y","year":"2019","unstructured":"Koyanagi Y, Kubo C, Nagata S,  Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary. Diagn Pathol 2019;14:9."},{"key":"B136","series-title":"Am J Surg Pathol","first-page":"1058","article-title":"Urothelial carcinoma involving the gynecologic tract: a morphologic and immunohistochemical study of 6 cases","volume":"36","author":"Reyes MC","year":"2012","unstructured":"Reyes MC, Park KJ, Lin O,  Urothelial carcinoma involving the gynecologic tract: a morphologic and immunohistochemical study of 6 cases. Am J Surg Pathol 2012;36:1058\u20131065."},{"key":"B137","series-title":"J Urol","first-page":"1751","article-title":"The management of clinically unconfirmed positive urinary cytology","volume":"150","author":"Schwalb DM","year":"1993","unstructured":"Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol 1993;150:1751\u20131756."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-p186.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-p186.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-p186.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:34Z","timestamp":1778754754000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-p186.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":274,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0022","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}